CDK4 and colorectal carcinoma: Our previous in vitro research demonstrated a strong synergistic effect between Palbociclib (CDK4/6 inhibitor) and Gedatolisib (PI3K inhibitor) in multiple CRC cell lines, regardless of mutation status [21].